Evidence map›Paper›PMID 35300743›Full record

ArticleInfection control and hospital epidemiology2022

A prospective, multicenter, clinical study of duodenoscope contamination after reprocessing.

Naoaki Okamoto, Anna Sczaniecka, Misa Hirano, Melinda Benedict, Shigeyoshi Baba, Yoko Horino, Masato Takenouchi, Yuichi Morizane, Ikuo Yana, Ross Segan and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Infection control and hospital epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Naoaki OkamotoMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Anna SczanieckaGyrus ACMI, (Olympus Surgical Technologies America), Redmond, Washington.
Misa HiranoMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Melinda BenedictMedical & Scientific Affairs, Olympus Corporation of the Americas, Center Valley, Pennsylvania.
Shigeyoshi BabaMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Yoko HorinoMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Masato TakenouchiMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Yuichi MorizaneMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Ikuo YanaMedical & Scientific Affairs, Olympus Corporation, Hachioji, Tokyo, Japan.
Ross SeganMedical & Scientific Affairs, Olympus Corporation of the Americas, Center Valley, Pennsylvania.
Lionel PineauEurofins Biotech Germande France, Marseille, France.
Michelle J AlfaDepartment of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSeveral clinical procedures utilize duodenoscopes, which are processed for reuse after the procedures are completed. However, infection outbreaks due to improper duodenoscope processing occur frequently. To address this, we aimed to assess the contamination rates of duodenoscopes after reprocessing in nonoutbreak settings. DESIGN AND

settingProspective study in 16 clinical sites in the United States.

methodsWe sampled and cultured reprocessed duodenoscopes following the FDA/CDC/ASM guideline; "Duodenoscope Surveillance Sampling and Culturing - Reducing the Risks of Infection." High-concern (HC) organisms were those highly associated with disease, including gram-negative rods,

resultsWe assessed 859 newer-model (NM) duodenoscopes (TJF-Q180V) and 850 older-model (OM) duodenoscopes (TJF-160F/VF); of these, 35 NM samples (4.1%) and 56 OM samples (6.6%) were contaminated with HC organisms. We detected and classified the HC organisms as gastrointestinal (45.4%), human origin (16.7%), environmental (24.1%), waterborne (13.0%), and unidentified (0.9%).

conclusionsWe detected an overall HC contamination rate of 5.3% in nonoutbreak settings. Although the relationship between endoscopic contamination and the occurrence of infections remains unclear, attempts should continue to be made to further reduce contamination rates. Additional improvements to the manufacturer's instructions for use, human factors during the reprocessing procedure, ongoing training programs, cleanliness of reprocessing environments, and the design of the distal end of the duodenoscope should be considered.

Indexed as

DuodenoscopesEquipment ContaminationDisease OutbreaksDisinfectionGram-Negative BacteriaHumansProspective Studies

Identifiers

PMID35300743
PMCPMC9753065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.